Trial Profile
A phase IIb trial to evaluate the efficacy and safety of intranasal oxytocin (TI-001) in patients with migraine
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 01 Apr 2016
Price :
$35
*
At a glance
- Drugs Oxytocin (Primary)
- Indications Migraine
- Focus Therapeutic Use
- 01 Apr 2016 New trial record
- 30 Mar 2016 According to a Trigemina media release, this trial is expected to start later this year 2016.